Agenus Inc. (NASDAQ:AGEN) has been given an average rating of "Buy" by the six ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $7.00.
A number of equities research analysts have issued reports on the stock. Jefferies Financial Group upped their price objective on shares of Agenus from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, September 18th. Zacks Investment Research downgraded shares of Agenus from a "hold" rating to a "sell" rating in a research report on Wednesday, October 7th. William Blair reaffirmed a "buy" rating on shares of Agenus in a research report on Wednesday, September 23rd. BidaskClub raised shares of Agenus from a "sell" rating to a "hold" rating in a research report on Friday, September 11th. Finally, B. Riley reiterated a "buy" rating and issued a $6.00 target price on shares of Agenus in a research note on Monday, June 22nd.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. boosted its stake in Agenus by 32.6% in the second quarter. Vanguard Group Inc. now owns 7,795,261 shares of the biotechnology company's stock valued at $30,636,000 after acquiring an additional 1,918,471 shares during the last quarter. Oracle Investment Management Inc. lifted its stake in Agenus by 25.4% in the 2nd quarter. Oracle Investment Management Inc. now owns 6,722,460 shares of the biotechnology company's stock worth $26,419,000 after purchasing an additional 1,361,593 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Agenus in the 3rd quarter worth approximately $3,237,000. Artal Group S.A. lifted its stake in Agenus by 14.0% in the 2nd quarter. Artal Group S.A. now owns 2,850,000 shares of the biotechnology company's stock worth $11,201,000 after purchasing an additional 350,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Agenus by 37.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 986,829 shares of the biotechnology company's stock worth $3,879,000 after purchasing an additional 268,923 shares in the last quarter. Hedge funds and other institutional investors own 49.07% of the company's stock.
NASDAQ:AGEN opened at $4.38 on Friday. The firm has a 50-day moving average of $4.36 and a 200-day moving average of $3.54. The company has a market cap of $803.48 million, a PE ratio of -3.84 and a beta of 1.98. Agenus has a one year low of $1.82 and a one year high of $5.63.
Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). The firm had revenue of $26.95 million for the quarter, compared to the consensus estimate of $9.33 million. As a group, equities research analysts predict that Agenus will post -1.02 earnings per share for the current year.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies.
Read More: Stochastic Momentum Index (SMI)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
10 Oversold Stocks That Are Ready For a Comeback
A fundamental concept of investing is to buy stocks at a value. One strategy used by investors is to focus on stocks that are oversold. Fundamental analysis can give investors an idea of certain stocks to look at. However, momentum is also important. For that reason, investors look for technical indicators to help them find oversold stocks that might be ready for a comeback.
One of the most popular tools is the Relative Strength Index (RSI). The RSI is a momentum indicator that measures the velocity and magnitude of price movements. The index also compares them with the magnitude of average gains and average losses.
The formula for calculating RSI is as follows:
RSI = 100 - ( 100 / 1 + RS)
Where RS (Relative Strength) is the average gain divided by the average loss.
Investors can use virtually any timeframe they wish. One of the most common is a 14-day RSI. Decreasing the number of days makes the RSI more sensitive to price changes. Conversely increasing the number of days makes the indicator less sensitive to price changes.
Investors may have different overbought or oversold indicators, but standard benchmarks are a stock may be overbought if its RSI exceeds 70 and may be oversold if its RSI exceeds 30.
The stocks in this presentation are chosen for a variety of fundamental and technical indicators. And all the stocks have been affected in one form or another by the Covid-19 pandemic.
View the "10 Oversold Stocks That Are Ready For a Comeback".